Loading…
Calcimedica Inc Is A Clinical-Stage Biopharmaceutical Company Focused On Developing Therapeutics That Treat Serious Illnesses Driven By Inflammatory And Immunologic Processes And Direct Cellular Damage. Its Product Candidates Act Upon Calcium Release-Activated Calcium (Crac) Channels And Would Constitute A New Class Of Drugs. Its Product Candidate Is Auxora, A Potent And Selective Intravenous Formulated Small Molecule Crac Channel Inhibitor Containing The Active Compound Zegocractin (Formerly Referred To As Cm4620) That, In Animal Models, Reduced Acute Epithelial And/Or Endothelial Cell Injury And Inflammation In Organs, Such As The Pancreas, Lungs And Kidneys. The Company Operates As One Operating Segment Focused On Developing And Commercializing Therapeutics In The U.S.